Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 2/20 | 0.37 |
| ▸ | FDPS | P14324 | 2/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 9/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27287931 | 0.92 | FDPS (0.33) | FDPSALDH1A1 | |
| SCHEMBL19645211 | 0.92 | SMPD1 (0.39) | SMPD1FDPSDNM1MEN1KMT2A | |
| SCHEMBL18823282 | 0.92 | SMPD1 (0.39) | SMPD1FDPSDNM1MEN1KMT2A | |
| SCHEMBL19387369 | 0.90 | SMPD1 (0.38) | SMPD1FDPSDNM1MEN1KMT2A | |
| SCHEMBL13735176 | 0.85 | SMPD1 (0.33) | SMPD1FDPSDNM1MEN1KMT2A | |
| SCHEMBL24027192 | 0.81 | OPRM1 (0.34) | SMPD1FDPSALDH1A1 | |
| SCHEMBL22624215 | 0.81 | CES2 (0.35) | — | |
| SCHEMBL21230013 | 0.79 | FDPS (0.33) | FDPSALDH1A1 | |
| SCHEMBL24943454 | 0.76 | OPRM1 (0.37) | SMPD1FDPSDNM1MEN1KMT2A | |
| SCHEMBL3912852 | 0.74 | LMNA (0.38) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10603386-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | SMPD1 1764/4885FDPS 3265/4885DNM1 2053/4885 |
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | SMPD1 2102/4885FDPS 3282/4885DNM1 1990/4885 |
| US-10603386-B2 | Protein-polymer-drug conjugates | PBRM1, CLTB, BRAP | SMPD1 2171/4885FDPS 3312/4885DNM1 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.